How does Viking's weight loss med compare to ones from Novo, Eli Lilly?

Jon Feingersh Photography Inc/DigitalVision via Getty Images Data reported earlier Monday from Viking Therapeutics ( NASDAQ: VKTX ) on its weight loss medicine VK2735 indicates that Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), which currently dominate the obesity drug space, could face competition. VK2735, which is being developed in both as.